Related Experiment Video
Updated: Mar 14, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease
Kailash Prasad1, Indu Dhar2, Qifeng Zhou3
1Department of Physiology, College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, S7N 5E5, Canada. k.prasad@usask.ca.
Abstract:
Interaction of advanced glycation end products (AGEs) with its cell-bound receptor (RAGE) results in cell dysfunction through activation of nuclear factor kappa-B, increase in expression and release of inflammatory cytokines, and generation of oxygen radicals. Circulating soluble receptors, soluble receptor (sRAGE), endogenous secretory receptor (esRAGE) and cleaved receptor (cRGAE) act as decoy for RAGE ligands and thus have cytoprotective effects. Low levels of sRAGE and esRAGE have been proposed as biomarkers for many diseases. However sRAGE and esRAGE levels are elevated in diabetes and chronic renal diseases and still tissue injury occurs. It is possible that increases in levels of AGEs are greater than increases in the levels of soluble receptors in these two diseases. Some new parameters have to be used which could be an universal biomarkers for cell dysfunction. It is hypothesized that increases in serum levels of AGEs are greater than the increases in the soluble receptors, and that the levels of AGEs is correlated with soluble receptors and that the ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE are elevated in patients with end-stage renal disease (ESRD) and would serve as an universal risk marker for ESRD. The study subject comprised of 88 patients with ESRD and 20 healthy controls. AGEs, sRAGE and esRAGE were measured using commercially available enzyme linked immune assay kits. cRAGE was calculated by subtracting esRAGE from sRAGE. The data show that the serum levels of AGEs, sRAGE, cRAGE are elevated and that the elevation of AGEs was greater than those of soluble receptors. The ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE were elevated and the elevation was similar in AGEs/sRAGE and AGEs/cRAGE but greater than AGEs/esRAGE. The sensitivity, specificity, accuracy, and positive and negative predictive value of AGEs/sRAGE and AGEs/cRAGE were 86.36 and 84.88 %, 86.36 and 80.95 %, 0.98 and 0.905, 96.2 and 94.8 %, and 61.29 and 56.67 % respectively. There was a positive correlation of sRAGE with esRAGE and cRAGE, and AGEs with esRAGE; and negative correlation between sRAGE and AGEs/sRAGE, esRAGE and AGES/esRAGE, and cRAGE and AGES/cRAGE. In conclusion, AGEs/sRAGE, AGEs/cRAGE and AGEs/esRAGE may serve as universal risk biomarkers for ESRD and that AGEs/sRAGE and AGEs/cRAGE are better risk biomarkers than AGEs/esRAGE.
Insights
Ratios of advanced glycation end products (AGEs) to soluble receptors (sRAGE, esRAGE, cRAGE) show promise as universal risk biomarkers for end-stage renal disease (ESRD). These AGEs/receptor ratios, particularly AGEs/sRAGE and AGEs/cRAGE, demonstrate significant diagnostic value for ESRD.
Area of Science:
- Biochemistry
- Nephrology
- Biomarker Discovery
Background:
- Advanced glycation end products (AGEs) interact with receptor for AGEs (RAGE), causing cell dysfunction via NF-κB activation, inflammatory cytokine release, and oxidative stress.
- Soluble RAGE variants (sRAGE, esRAGE, cRAGE) act as decoys, offering cytoprotection, but their levels are often elevated in diseases like diabetes and chronic renal disease, despite ongoing tissue injury.
- The imbalance between AGEs and soluble RAGE levels in certain diseases suggests a need for novel biomarkers to assess cell dysfunction universally.
Purpose of the Study:
- To investigate the hypothesis that serum AGEs levels increase disproportionately more than soluble RAGE levels in end-stage renal disease (ESRD).
- To evaluate the potential of AGEs/sRAGE, AGEs/esRAGE, and AGEs/cRAGE ratios as universal risk biomarkers for ESRD.
- To determine the diagnostic accuracy of these ratios in distinguishing ESRD patients from healthy controls.
Main Methods:
- Serum samples from 88 ESRD patients and 20 healthy controls were analyzed.
- Levels of AGEs, sRAGE, and esRAGE were quantified using enzyme-linked immune assay kits.
- The level of cRAGE was calculated by subtracting esRAGE from sRAGE.
Main Results:
- Serum levels of AGEs, sRAGE, and cRAGE were elevated in ESRD patients, with AGEs showing a greater increase than soluble receptors.
- The ratios of AGEs/sRAGE, AGEs/esRAGE, and AGEs/cRAGE were significantly elevated in ESRD patients.
- AGEs/sRAGE and AGEs/cRAGE exhibited high sensitivity (86.36% and 84.88%) and specificity (86.36% and 80.95%), indicating strong diagnostic potential.
Conclusions:
- The ratios AGEs/sRAGE, AGEs/cRAGE, and AGEs/esRAGE may serve as effective universal risk biomarkers for ESRD.
- AGEs/sRAGE and AGEs/cRAGE are identified as superior risk biomarkers compared to AGEs/esRAGE for ESRD.
- These ratios offer valuable insights into the pathogenic mechanisms and diagnostic assessment of ESRD.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Nephrotic Syndrome I : Introduction
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Drug Toxicity: Risk factors
Acute Kidney Injury IV: Diagnostic Studies and Prevention

